Patents by Inventor Carl Pabo
Carl Pabo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7939327Abstract: Disclosed herein are compositions and methods that regulate expression of two or more endogenous genes.Type: GrantFiled: February 28, 2008Date of Patent: May 10, 2011Assignee: Sangamo Biosciences, Inc.Inventors: Jeffrey Miller, Guofu Li, Carl Pabo, Trevor Collingwood
-
Publication number: 20080233641Abstract: Disclosed herein are compositions and methods that regulate expression of two or more endogenous genes.Type: ApplicationFiled: February 28, 2008Publication date: September 25, 2008Inventors: Jeffrey Miller, Guofu Li, Carl Pabo, Trevor Collingwood
-
Patent number: 7361635Abstract: Disclosed herein are compositions and methods that regulate expression of two or more endogenous genes.Type: GrantFiled: August 29, 2003Date of Patent: April 22, 2008Assignee: Sangamo Biosciences, Inc.Inventors: Jeffrey Miller, Guofu Li, Carl Pabo, Trevor Collingwood
-
Publication number: 20070178454Abstract: The present invention relates to methods of identifying multi-finger Zf polypeptides that bind to a sequence of interest. Zf polypeptides identified using the methods described herein can have affinity and specificity for their target sites that is superior to those produced by alternative methods.Type: ApplicationFiled: October 23, 2003Publication date: August 2, 2007Inventors: J. Joung, Carl Pabo
-
Publication number: 20070149770Abstract: Polynucleotides encoding chimeric proteins, and methods for their production and use are disclosed. The chimeric proteins comprise a flexible linker between two zinc finger DNA-binding domains, wherein the linker contains eight or more amino acids between the second conserved histidine residue of the carboxy-terminal zinc finger of the first domain and the first conserved cysteine residue of the amino-terminal zinc finger of the second domain.Type: ApplicationFiled: December 14, 2006Publication date: June 28, 2007Applicant: Massachusetts Institute of TechnologyInventors: Jin-Soo Kim, Carl Pabo
-
Publication number: 20070150973Abstract: Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.Type: ApplicationFiled: March 7, 2006Publication date: June 28, 2007Inventors: Joel Pomerantz, Phillip Sharp, Carl Pabo
-
Publication number: 20050202498Abstract: Polynucleotides encoding chimeric proteins, and methods for their production and use are disclosed. The chimeric proteins comprise a flexible linker between two zinc finger DNA-binding domains, wherein the linker contains eight or more amino acids between the second conserved histidine residue of the carboxy-terminal zinc finger of the first domain and the first conserved cysteine residue of the amino-terminal zinc finger of the second domain.Type: ApplicationFiled: April 20, 2005Publication date: September 15, 2005Applicant: Massachusetts Institute of TechnologyInventors: Jin-Soo Kim, Carl Pabo
-
Publication number: 20050064474Abstract: Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.Type: ApplicationFiled: August 6, 2004Publication date: March 24, 2005Inventors: Fyodor Urnov, Michael Holmes, Jeffrey Miller, Carl Pabo
-
Publication number: 20050064477Abstract: The present invention provides methods and compositions for interaction trap assays for detecting protein-protein, protein-DNA, or protein-RNA interactions. The methods and compositions of the invention may also be used to identify agents which may agonize or antagonize a protein-protein, protein-DNA, or protein-RNA interactions. In certain embodiments, the interaction trap system of the invention is useful for screening libraries with greater than 107 members. In other embodiments, the interaction trap system of the invention is used in conjunction with flow cytometry. The invention further provides a means for simultaneously screening a target protein or nucleic acid sequence for the ability to interact with two or more test proteins or nucleic acids.Type: ApplicationFiled: August 10, 2004Publication date: March 24, 2005Inventors: J. Joung, Jeffrey Miller, Carl Pabo
-
Publication number: 20040091991Abstract: Disclosed herein are compositions and methods that regulate expression of two or more endogenous genes.Type: ApplicationFiled: August 29, 2003Publication date: May 13, 2004Applicant: Sangamo BioSciences, Inc.Inventors: Jeffrey Miller, Guofu Li, Carl Pabo, Trevor Collingwood
-
Patent number: 6316003Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which include HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.Type: GrantFiled: April 28, 1994Date of Patent: November 13, 2001Assignees: Whitehead Institute for Biomedical Research, Johns Hopkins Univ. School of Medicine, Biogen, Inc.Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
-
Patent number: 5804604Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.Type: GrantFiled: May 25, 1995Date of Patent: September 8, 1998Assignee: Biogen, Inc.Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
-
Patent number: 5747641Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.Type: GrantFiled: May 25, 1995Date of Patent: May 5, 1998Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
-
Patent number: 5674980Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.Type: GrantFiled: May 25, 1995Date of Patent: October 7, 1997Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
-
Patent number: 5670617Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.Type: GrantFiled: May 25, 1995Date of Patent: September 23, 1997Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
-
Patent number: 5652122Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.Type: GrantFiled: May 25, 1995Date of Patent: July 29, 1997Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky